Urogen Pharma Ltd. URGN
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
UroGen Pharma Ltd. is an Israel-based biopharmaceutical company specializing in innovative treatments for urological cancers and diseases. The company develops therapies using its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release platform that enhances drug delivery directly to targeted tissues…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees298
TickerURGN
Statistics
Market Cap$1.59B
Revenue (TTM)$109.8M
Net Income-$153.5M
Net Margin-139.8%
EPS—
P/E-9.22
P/S10.23
P/B-11.87
EV/EBITDA-13.17
ROE145.5%
Dividend Yield—
Price$32.62
Data: Twelve Data · Revenue = mcap / P/S